Answers are grounded in this paper and cite their sources.
C linical guidelines 1,2 advocate the use of oral anticoagu- lation, whether a vitamin K antagonist (VKA) or 1 of the novel agents, for stroke prevention in patients with atrial fibrillation who have ≥1 risk factors for stroke.The benefits of traditional oral anticoagulants (VKAs), in terms of a reduction in stroke and major bleeding events, are experienced only over a narrow therapeutic window (international normalized ratio [INR] of 2.0-3.0).Their intricate pharmacokinetic profile with a slow onset and offset of action and numerous drug, food, and alcohol interactions, as well as genetic, ethnicity, and age-related differences in dose response, necessitates regular INR monitoring.
No takes yet. Share an insight, caveat, or question.
Gallego et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: